A Phase 2a dose‐escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS‐986231 in hospitalized patients with heart failure with reduced ejection fraction

AIMS: This study was designed to evaluate the safety, tolerability and haemodynamic effects of BMS‐986231, a novel second‐generation nitroxyl donor with potential inotropic, lusitropic and vasodilatory effects in patients hospitalized with decompensated heart failure and reduced ejection fraction (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Tita, Cristina, Gilbert, Edward M., Van Bakel, Adrian B., Grzybowski, Jacek, Haas, Garrie J., Jarrah, Mohammad, Dunlap, Stephanie H., Gottlieb, Stephen S., Klapholz, Marc, Patel, Parag C., Pfister, Roman, Seidler, Tim, Shah, Keyur B., Zieliński, Tomasz, Venuti, Robert P., Cowart, Douglas, Foo, Shi Yin, Vishnevsky, Alexander, Mitrovic, Veselin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2017
Materias:
New Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607490/
https://www.ncbi.nlm.nih.gov/pubmed/28677877
http://dx.doi.org/10.1002/ejhf.897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607490/
https://www.ncbi.nlm.nih.gov/pubmed/28677877
http://dx.doi.org/10.1002/ejhf.897

Ejemplares similares